• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CRO Quintiles Opens First Prime Site in Asia

CRO Quintiles Opens First Prime Site in Asia

July 14, 2010
CenterWatch Staff

Global CRO Quintiles announced a strategic alliance agreement with the University Malaya Medical Centre (UMMC) in Malaysia as part of its Prime Site program, an initiative focused on accelerating the development of new and more effective medicines.

The UMMC is the first Prime Site in Asia for Quintiles, adding to its existing four sites in the U.S., Europe and Africa. “Prime Sites are large clinical institutions that collaborate with Quintiles to enhance their infrastructure for conducting clinical trials,” said Christopher Cabell, M.D. “The University Malaya Medical Centre is an ideal partner for us because of its experience in conducting clinical research, its access to substantial patient populations and its clinical expertise across multiple therapeutic areas.”

A pioneer in the Asia-Pacific clinical research industry, Quintiles opened its first office there in 1993. Since then, the company has grown to more than 20 offices in 14 countries throughout the region, and has conducted more than 1,300 studies involving more than 9,000 sites and 185,000 patients. In related news, Quintiles is investing up to $2 million in Australia’s Prana Biotechnology.

According to Prana, Quintiles has been “intimately involved” for a number of years with the Melbourne-based company, formed in 1997 to commercialize research into Alzheimer’s disease and other major age-related neurodegenerative disorders. Quintiles was the research partner for Prana’s last successful clinical trial.

Quintiles will help support a planned definitive phase II study with PBT2, the biotechnology company’s lead compound for Alzheimer’s disease, with 525 patients with mild to moderate Alzheimer’s disease for a treatment period of 12 months, with cognition the key performance measure.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing